Benjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 1,000 shares of the company’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $25.04, for a total value of $25,040.00. Following the completion of the transaction, the chief financial officer now directly owns 13,000 shares of the company’s stock, valued at approximately $325,520. The trade was a 7.14 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.51, for a total value of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.15, for a total value of $74,202.50.
• On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.89, for a total transaction of $130,672.50.
• On Monday, October 28th, Benjamin Hohl sold 6,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $28.56, for a total transaction of $178,500.00.
• On Friday, October 18th, Benjamin Hohl sold 814 shares of Enliven Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $24,420.00.

Enliven Therapeutics Stock Up 1.2 %

ELVN stock opened at $24.15 on Thursday. The company’s fifty day simple moving average is $24.74 and its 200 day simple moving average is $24.39. Enliven Therapeutics, Inc. has a 12-month low of $10.90 and a 12-month high of $30.03. The firm has a market cap of $1.18 billion, a price-to-earnings ratio of -12.71 and a beta of 1.04.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ELVN. HC Wainwright reaffirmed a “buy” rating and set a $37.00 target price on shares of Enliven Therapeutics in a research report on Tuesday, October 1st. Robert W. Baird increased their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a research note on Friday, November 15th. Finally, BTIG Research initiated coverage on Enliven Therapeutics in a research note on Friday, December 13th. They issued a “buy” rating and a $42.00 price objective on the stock. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $38.25.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC increased its holdings in Enliven Therapeutics by 10.6% in the third quarter. FMR LLC now owns 6,296,179 shares of the company’s stock worth $160,804,000 after purchasing an additional 601,611 shares in the last quarter. First Turn Management LLC bought a new stake in shares of Enliven Therapeutics in the 2nd quarter valued at $9,657,000. Lord Abbett & CO. LLC acquired a new position in shares of Enliven Therapeutics during the 3rd quarter valued at $8,199,000. Janus Henderson Group PLC lifted its position in shares of Enliven Therapeutics by 43.0% during the 3rd quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company’s stock valued at $26,611,000 after acquiring an additional 313,019 shares during the period. Finally, Ally Bridge Group NY LLC bought a new position in Enliven Therapeutics during the third quarter worth $5,998,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.